These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851 [TBL] [Abstract][Full Text] [Related]
19. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974 [TBL] [Abstract][Full Text] [Related]
20. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]